VEGFR-2-IN-24

VEGFR-2-IN-24 is a potent VEGFR-2 inhibitor with IC50 value of 0.22 µM. VEGFR-2-IN-24 can be used for tumor research[1].

Research Areas >> Cancer

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> VEGFR

VEGFR2:0.22 μM (IC50)

VEGFR-2-IN-24 (Compound 8f) (0-1000 μM, 72 hours; human tumor cell lines) exerts the most potent antitumor activities against human cancer cell lines[1]. VEGFR-2-IN-24 (Compound 8f) (0-1000 μM, 72 hours; human tumor cell lines) displays the highest anticancer activities with IC50 values of 11.19, 8.99 and 7.10 μM for HepG2, HCT-116 and MCF-7 cell lines, respectively[1]. VEGFR-2-IN-24 (Compound 8f) (0-300 μg/mL, 5 min) remarkably exhibits VEGFR-2 inhibition with IC50 value of 0.22 µM[1]. Cell Cytotoxicity Assay[1] Cell Line: Hepatocellular carcinoma (HepG2), breast cancer (MCF-7) and colorectal carcinoma (HCT-116). Concentration: 0.1, 10, 100 and 1000 µM Incubation Time: 72 hours Result: Inhibited with IC50 values of 11.19, 8.99 and 7.10 μM for HePG-2, MCF-7 and HCT-116, respectively.

[1]. El-Adl K, et al. Design, synthesis, molecular docking and anticancer evaluations of 5-benzylidenethiazolidine-2,4-dione derivatives targeting VEGFR-2 enzyme. Bioorg Chem. 2020 Sep;102:104059.